ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

WSJ BLOG/Health: A.M. Vitals: GSK's Hostile Human Genome Bid; Regulators Like Preventive HIV Drug

(This story has been posted on The Wall Street Journal Online's Health Blog at By Christopher Weaver Here's what's making health news this morning: The ABCs of Beating Obesity (WSJ): A new Institute of Medicine report says schools should be a "national focal point" for the prevention of obesity, requiring, for instance, at least 60 minutes of physical activity a day. GSK Makes Hostile Human Genome Sciences Bid (WSJ): GlaxoSmithKline said it would take a $2.6 billion bid to buy Human Genome directly to shareholders after its smaller partner rejected the offer as too low. Regulator Seems to Back HIV Drug (WSJ): A memo released by Food and Drug Administration regulators Tuesday said Gilead Sciences' drug Truvada could spare people at risk for HIV "infection with a serious and life-threatening illness," a sign of support for what would be the first approval of a preventive HIV medicine. Psychiatry Manual Drafters Back Down on Diagnoses (New York Times): Amid protests from therapists, scientists and patients, the nation's top psychiatry association stripped its forthcoming index of diseases of two new disorders it concluded were not supported by evidence. Senate Inquiry Into Painkiller Makers' Ties (New York Times): Senators are probing ties between pharmaceutical companies that make pain pills and the patient groups, pain specialists and other groups that have advocated for broader use of the drugs. Retired Couples May Need $240,000 for Health Care (Associated Press): Fidelity Investments estimates that retired couples will need to reserve $240,000 for health care costs over the remainder of their lives, a number that could rise if the 2010 federal health law is repealed. -For continuously updated news from The Wall Street Journal, see at

Stock News for Gilead Sciences (GILD)
11/29/201614:46:04Statement of Changes in Beneficial Ownership (4)
11/29/201614:13:36Statement of Changes in Beneficial Ownership (4)
11/28/201608:30:00Innovative Clinical Trial Implementation and Manufacturing Capacity...
11/23/201608:13:00Gilead Sciences Canada, Inc., se voit décerner le prestigieux...
11/23/201608:10:00Gilead Sciences Canada, Inc., is awarded prestigious Prix Galien...
11/22/201614:46:39Statement of Changes in Beneficial Ownership (4)
11/21/201613:10:15Initial Statement of Beneficial Ownership (3)
11/16/201617:00:00Gilead Sciences Announces Promotion of James R. Meyers to Executive...
11/16/201616:15:00Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating...
11/15/201617:00:00Gilead Sciences to Present at the Annual Piper Jaffray Healthcare...
11/14/201616:30:00Medicare Identifies Which Prescription Drugs Were Costliest in...
11/14/201616:30:00Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis...
11/14/201613:04:40Statement of Changes in Beneficial Ownership (4)
11/11/201607:25:00European CHMP Adopts Positive Opinion for Gilead’s Vemlidy® (T...
11/10/201613:06:00U.S. Food & Drug Administration Approves Gilead’s Vemlidy® (T...
11/07/201617:32:13Quarterly Report (10-q)
11/03/201618:11:28Statement of Changes in Beneficial Ownership (4)
11/02/201609:52:00U.S. Hot Stocks: Hot Stocks to Watch
11/01/201617:30:00Gilead Sales of Hepatitis C Drugs Harvoni and Sovaldi Slump
11/01/201617:17:00Gilead Sales of Hepatitis C Drugs Harvoni and Sovaldi Slump Under...

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations